Market Research Reports and Industry Reports

Non-Alcoholic SteatoHepatitis (NASH): An Analysis of Disease Prevalence, Drugs in development, Regulatory guidelines and Market opportunity in Various Geographies

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • PURCHASE BY
    SECTION
Sales of Hepatitis C drugs crossed ~$10bn in 2014 proving that treatments for liver disease could become mega-blockbusters and Non-Alcoholic SteatoHepatitis (NASH) is expected to be equally lucrative. Improved diagnosis rate and change in treatment guidelines along with defined clinical trials endpoint are the concerns for the emerging therapy. US FDA is expected to release guidelines for the clinical trial in CY16 and this should accelerate the development of the drugs targeting NASH.

NASH is the progressive form of Non-Alcoholic Fatty Liver Disease NAFLD. While NASH can reverse itself, in many cases, the resulting liver scarring causes a patients liver to harden and failure to work properly. It is estimated that NASH affects 2 to 5% of the US population. Other developed countries such as Europe and Japan also have similar or higher incidence of NASH disease. Due to the varying physical and metabolism traits across various geographies, development of drugs for NASH is facing difficulty. In Japan, the prevalence of NASH is rising although the population is not typically overweight. Countries like India and China with bigger population and changes in lifestyles face a greater risk of NASH along with other lifestyle diseases like Diabetes and Cardiovascular related complexities.

As per the US Association of Liver Disease, of those who develop NASH, ~15-25% will progress to end stage liver disease (ESLD) and hepatocellular carcinoma (HCC) over 10-20 years. Today, 1/3rd of Liver transplants and HCC are caused by NASH and the total cost burden of this on US is over ~$5 billion per year. Only new treatments in NASH could lead to a cut in this major cost burden along with improving quality of life.

Since a new innovation in NASH has been enlightened, the interest in companies developing drugs for NASH has also gone up. In Jan. 2015, Gilead Sciences (GILD) acquired Phenex Pharmas Farnesoid X Receptor (FXR) program comprising small molecule FXR agonists for the treatment of liver diseases including nonalcoholic steatohepatitis (NASH) and other Liver Diseases. Merck-NGM Biopharma and Boehringer Ingelheim - Pharmaxis also entered into an exclusive agreement for the pipeline products which are being developed for NASH with a potential deal value of ~$450-600mn.

This report will provide detailed analysis on NASH disease and Drugs in development in broader pharma market. This report list all the drugs in clinical trial and their design and the population recruited, also tells about the pathways representing possible targets for the treatment of NASH.
1 Nonalcoholic steatohepatitis: Ongoing clinical trials
2 Pathways representing possible targets for the treatment of NASH
3 Drugs in Development
4 Failed/ Discontinued drugs
5 Select deals in the field of NASH
6 Potential licensing/ M&A opportunities
7 Drugs in development for NASH and Target
8 Noninvasive diagnostic methods for NAFLD
9 PIVENS trial: Primary outcomes after 96 weeks of treatment
10 PIVENS trial: Secondary outcomes after 96 weeks of treatment
11 PIVENS trial: Safety outcomes after 96 weeks of treatment
12-14 NASH disease market opportunity to 2025 in US, Europe, and Japan

List Of Tables

1 Putative mechanisms underlying the contribution of NAFLD
2 Progression of NAFLD to NASH
3 Various modes of FXR gene regulation
4 Elafibranor: Mechanism of Action
5 Comparison GOLDEN/ FLINT/ PIVENS: Efficacy in the NAS > 4 Phase III target population
6 A. GOLDEN-505: Cardio-Metabolic protection
B. GOLDEN-505: Glycemic parameters in diabetics
7 Simtuzumab: LOXL2 pathway
8 GS-4997: ASK1 in insulin resistance
9 Emricasan: Phase II data @ EASL 2015
10 Emricasan: Phase II data @ AASLD 2015
11 Aramchol: Phase IIa data relative change in liver-fat concentration
12 Cenicriviroc (CVC): A potent inhibitor of infiltration of pro-inflammatory monocytes
13 Cenicriviroc (CVC): Lipid Profile Changes from Baseline
14 Results from PhI/IIa trial: Efficacy of IMM-124E
15 GR-MD-02: PhI study Serum Biomarkers Evaluation

16 GR-MD-02: Preclinical data Tx effect on NASH with fibrosis
17 LEAN study: Schematic of the trial design
18 Forms of fatty liver disease
19 Pivotal role of activated Kupffer cells in the pathogenesis of NASH and fibrogenesis

20 Companion diagnostics: The potential endpoints

21 Polyherbal therapeutic approaches available for the management of NASH

List Of Figures

1 Nonalcoholic steatohepatitis: Ongoing clinical trials
2 Pathways representing possible targets for the treatment of NASH
3 Drugs in Development
4 Failed/ Discontinued drugs
5 Select deals in the field of NASH
6 Potential licensing/ M&A opportunities
7 Drugs in development for NASH and Target
8 Noninvasive diagnostic methods for NAFLD
9 PIVENS trial: Primary outcomes after 96 weeks of treatment
10 PIVENS trial: Secondary outcomes after 96 weeks of treatment
11 PIVENS trial: Safety outcomes after 96 weeks of treatment
12-14 NASH disease market opportunity to 2025 in US, Europe, and Japan

United States Non-alcoholic Concentrated Syrup Market Report 2016

Notes:Sales, means the sales volume of Non-alcoholic Concentrated SyrupRevenue, means the sales value of Non-alcoholic Concentrated SyrupThis report studies sales (consumption) of Non-alcoholic Concentrated Syrup in United States market, focuses

USD 3800View Report

United States Non-Alcoholic Drinks Market Report 2016

Notes:Sales, means the sales volume of Non-Alcoholic DrinksRevenue, means the sales value of Non-Alcoholic DrinksThis report studies sales (consumption) of Non-Alcoholic Drinks in United States market, focuses on the top

USD 3800View Report

Global Non-alcoholic Concentrated Syrup Market Research Report 2016

Notes:Production, means the output of Non-alcoholic Concentrated SyrupRevenue, means the sales value of Non-alcoholic Concentrated SyrupThis report studies Non-alcoholic Concentrated Syrup in Global market, especially in North America, Europe, China,

USD 2900View Report

United States, EU, Japan, China, India and Southeast Asia Non-Alcoholic Steatohepatitis Clinical Trials Market Size, Status and Forecast 2021

Notes:Production, means the output of Non-Alcoholic Steatohepatitis Clinical TrialsRevenue, means the sales value of Non-Alcoholic Steatohepatitis Clinical TrialsThis report studies the global Non-Alcoholic Steatohepatitis Clinical Trials market, analyzes and researches

USD 3300View Report

Nonalcoholic Steatohepatitis (NASH): KOL Insight

Who will benefit most from huge opportunities in NASH treatmentThe first new NASH therapy is due soon: but is it safe and effective enough How happy are KOLs with the

USD 7900View Report

Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2016

Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2016Global Markets Directs, Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2016, provides an overview of the Non-Alcoholic Steatohepatitis pipeline landscape. The report provides comprehensive information

USD 2000View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
If you want to purchase particular section from this report then kindly contact us at contact@aarkstore.com.

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    $ 3500
  • Site Licence    $ 7000
  • Enterprisewide Licence    $ 10500
$ 3500

Reports Details

Published Date : Dec 2015
No. of Pages :65
Country :Global
Category :Healthcare
Publisher :MP Advisors
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment